FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine;

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Description:
  On December 4, 2008, the Food and Drug Administration (FDA) approved an expanded age indication for the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) Boostrix (GlaxoSmithKline Biologicals, Rixensart, Belgium). Boostrix is now licensed for use in persons aged 10--64 years as a single-dose booster immunization; the vaccine initially was licensed for persons aged 10--18 years. This announcement summarizes the indications for use of Boostrix. Complete recommendations of the Advisory Committee on Immunization Practices (ACIP) for Tdap vaccines have been described previously (1--3).
• Subjects:
  Adolescent Adult Age Factors Child Clinical Trials As Topic Diphtheria-Tetanus-Pertussis Vaccine Drug Approval Humans Immunization Schedule Influenza Vaccines Middle Aged Young Adult

  More +
• Source:
  MMWR. Morbidity and mortality weekly report. 2009; 58(14):374-5.
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Journal Article
• Name as Subject:
  United States. Food and Drug Administration. ; United States. Food and Drug Administration.
• Place as Subject:
  United States
• Pages in Document:
  2 pdf pages
• Volume:
  58
• Issue:
  14
• Collection(s):
  Guidelines and Recommendations Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:537b3c8d03ba5455e4105625dd4808dfde85d2a1bf4acaa175ac7c71e6d7ecdfea4f0304009a8140b7b40fe6b0529c3d9ee506173e8f4bfae88b950d91592d77
• Download URL:
  https://stacks.cdc.gov/view/cdc/7438/cdc_7438_DS1.pdf
• File Type:
  [PDF - 2.07 MB ]